Elsevier

Experimental Neurology

Volume 322, December 2019, 113057
Experimental Neurology

Review Article
Potential roles of matricellular proteins in stroke

https://doi.org/10.1016/j.expneurol.2019.113057Get rights and content

Highlights:

  • Outcomes of ischemic and hemorrhagic strokes are still poor.

  • The pathophysiology of stroke-induced brain injury remains poorly understood.

  • There are many matricellular proteins that are induced and have diverse functions.

  • Many matricellular proteins are involve in stroke pathophysiology.

  • Some matricellular proteins are harmful whereas others are protective.

Abstract

Both ischemic and hemorrhagic strokes are still serious diseases with high mortalities and morbidities. To improve outcomes of strokes, new therapeutic approaches need to be developed. Matricellular proteins are inducible, multifunctional and non-structural extracellular matrix proteins, which are definitely differentiated from classical ones due to the unusual diversity of functions. There are many matricellular proteins known, most of which may be involved in the pathophysiology and the protective or repairing mechanisms of strokes. This article reviews the available information regarding potential roles of matricellular proteins in stroke, and discusses the potential therapeutic approaches against stroke using matricellular proteins.

Introduction

Irrespective of recent advances in stroke treatment, stroke remains a leading cause of long-term disabilities with different risk factors depending on stroke subtypes (O'Donnell et al., 2016). To improve outcomes of both ischemic and hemorrhagic strokes, further basic researches are needed to clarify the mechanisms of progression or regression of brain injury in each stroke subtype, which would lead to future development of new brain protection therapies.

Matricellular proteins are inducible and secretory non-structural proteins belonging to the extracellular matrix proteins (Suzuki et al., 2018a). Due to the unusual diversity of functions, the term “matricellular protein” was introduced in 1995, and the number of matricellular proteins is still increasing (Suzuki et al., 2018a). It is the common features of matricellular proteins that they are readily upregulated in almost any tissue and cell type under pathological conditions, bind to many cell surface receptors, other matrix proteins, growth factors, cytokines, chemokines and proteases, and modulate cell–cell or cell–matrix interactions to control cellular morphology and behavior (differentiation, adhesion, migration, and survival or apoptosis) (Suzuki et al., 2018a). Although matricellular protein-deficient mice undergo normal development, matricellular proteins serve as key mediators of various physiological reactions during developmental stages as well as diverse pathological processes depending on the biological scenario surrounding its induction (Suzuki et al., 2018a). This review summarizes the available information of potential roles of matricellular proteins in stroke (Table 1), and discusses the possibility to target a matricellular protein and to develop new therapies against stroke.

Section snippets

Tenascin

Tenascins have 4 members (tenascin-C, -R, -W and -X) in vertebrates (Roll and Faissner, 2019), among which only tenascin-C has been implicated in stroke. Tenascin-C typically forms a hexamer, but alternative splicing of the fibronectin type III repeats, post-translational modifications and proteolytic processing produce lots of tenascin-C isoforms with various functions and sizes, which can be present simultaneously in the specific tissues (Suzuki et al., 2018a). In a developing stage, radial

Perspectives

Alterations in expressions of various matricellular proteins may be critically implicated in the pathophysiology of ischemic and hemorrhagic strokes, and can cause, suppress or repair brain injuries depending on the surrounding situations and the characteristics of the protein. Recent clinical application of machine learning analysis also demonstrated the importance of some matricellular proteins as a determinant on outcome measures in hemorrhagic stroke (Tanioka et al., 2019). As some of

Funding

This work was supported by a grant-in-aid for Scientific Research from Japan Society for the Promotion of Science (grant number 17K10825).

Declaration of Competing Interest

None.

Acknowledgements

We thank Chiduru Yamamoto-Nakamura (Department of Neurosurgery, Mie University Graduate School of Medicine) for her assistance with administrative support.

References (105)

  • S. Ishibashi et al.

    Galectin-1 regulates neurogenesis in the subventricular zone and promotes functional recovery after stroke

    Exp. Neurol.

    (2007)
  • W.J. Ji et al.

    Association between serum periostin concentrations and outcome after acute spontaneous intracerebral hemorrhage

    Clin. Chim. Acta

    (2017)
  • H. Kanamaru et al.

    Plasma periostin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

    Neurotherapeutics

    (2019)
  • Y. Liu et al.

    The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: a systematic review and meta-analysis involving 149,908 subjects

    Gene

    (2018)
  • M. Navarro-Sobrino et al.

    A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke

    Atherosclerosis

    (2011)
  • A.J. Obaya et al.

    The dual role of fibulins in tumorigenesis

    Cancer Lett.

    (2012)
  • M.J. O’Donnell et al.

    Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study

    Lancet

    (2016)
  • L. Roll et al.

    Tenascins in CNS lesions

    Semin. Cell Dev. Biol.

    (2019)
  • Y.F. Shen et al.

    The prognostic value of plasma thrombospondin-1 concentrations after aneurysmal subarachnoid hemorrhage

    Clin. Chim. Acta

    (2015)
  • L.G. Wang et al.

    Serum tenascin-C predicts severity and outcome of acute intracerebral hemorrhage

    Clin. Chim. Acta

    (2018)
  • H. Yan et al.

    Decorin alleviated chronic hydrocephalus via inhibiting TGF-β1/Smad/CTGF pathway after subarachnoid hemorrhage in rats

    Brain Res.

    (2016)
  • X.J. Yan et al.

    Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage

    J. Neurol. Sci.

    (2016)
  • A.L. Yang et al.

    Thrombin promotes the expression of thrombospondin-1 and -2 in a rat model of intracerebral hemorrhage

    J. Neurol. Sci.

    (2012)
  • A. Acar et al.

    Serum levels of calcification inhibitors in patients with intracerebral hemorrhage

    Int. J. Neurosci.

    (2012)
  • S.S. Baliga et al.

    Osteopontin expression during early cerebral ischemia-reperfusion in rats: enhanced expression in the right cortex is suppressed by acetaminophen

    PLoS One

    (2011)
  • F. Bonsack et al.

    Differential cellular expression of galectin-1 and galectin-3 after intracerebral hemorrhage

    Front. Cell. Neurosci.

    (2019)
  • F. Carbone et al.

    Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke

    Eur. J. Clin. Invest.

    (2015)
  • S.-L. Chan et al.

    Inhibition of PAI (plasminogen activator inhibitor)-1 improves brain collateral perfusion and injury after acute ischemic stroke in aged hypertensive rats

    Stroke

    (2018)
  • Z.Q. Chen et al.

    Negative regulation of glial Tim-3 inhibits the secretion of inflammatory factors and modulates microglia to antiinflammatory phenotype after experimental intracerebral hemorrhage in rats

    CNS Neurosci. Ther.

    (2019)
  • M. Dellett et al.

    Small leucine rich proteoglycan family regulates multiple signalling pathways in neural development and maintenance

    Dev. Growth Differ.

    (2012)
  • F. Denorme et al.

    Inhibition of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 reduces ischemic brain damage in mice

    Stroke

    (2016)
  • K.P. Doyle et al.

    Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke

    J. Cereb. Blood Flow Metab.

    (2008)
  • M. Fujimoto et al.

    Deficiency of tenascin-C and attenuation of blood-brain barrier disruption following experimental subarachnoid hemorrhage in mice

    J. Neurosurg.

    (2016)
  • M. Fujimoto et al.

    Effects of tenascin-C knockout on cerebral vasospasm after experimental subarachnoid hemorrhage in mice

    Mol. Neurobiol.

    (2018)
  • E.V. Griemert et al.

    PAI-1 but not PAI-2 gene deficiency attenuates ischemic brain injury after experimental stroke

    Transl. Stroke Res.

    (2018)
  • J. Guo et al.

    Overexpression of fibulin-5 attenuates ischemia/reperfusion injury after middle cerebral artery occlusion in rats

    Mol. Neurobiol.

    (2016)
  • X.W. He et al.

    Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke

    Sci. Rep.

    (2017)
  • X. He et al.

    Longitudinal evaluation of serum periostin levels in patients after large-artery atherosclerotic stroke: a prospective observational study

    Sci. Rep.

    (2018)
  • J.J. Hill et al.

    Intracerebral chondroitinase ABC and heparan sulfate proteoglycan glypican improve outcome from chronic stroke in rats

    Proc. Natl. Acad. Sci. U. S. A.

    (2012)
  • L. Hu et al.

    Fibulin-5: a novel biomarker for evaluating severity and predicting prognosis in patients with acute intracerebral haemorrhage

    Eur. J. Neurol.

    (2016)
  • X. Hu et al.

    Association between plasminogen activator inhibitor-1 genetic polymorphisms and stroke susceptibility

    Mol. Neurobiol.

    (2017)
  • Y. Hua et al.

    Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage

    J. Cereb. Blood Flow Metab.

    (2002)
  • K. Ikeda et al.

    Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage

    Neurosurgery

    (1997)
  • A.R. Jayakumar et al.

    Role of matricellular proteins in disorders of the central nervous system

    Neurochem. Res.

    (2017)
  • Y. Ji et al.

    Changes in the coagulation and fibrinolytic system of patients with subarachnoid hemorrhage

    Neurol. Med. Chir. (Tokyo)

    (2014)
  • H. Kanamaru et al.

    The role of periostin in brain injury caused by subarachnoid hemorrhage

    OBM Neurobiology

    (2019)
  • F. Kawakita et al.

    Periostin in cerebrovascular disease

    Neural Regen. Res.

    (2020)
  • A. Kudo

    Introductory review: periostin-gene and protein structure

    Cell. Mol. Life Sci.

    (2017)
  • T. Kunnas et al.

    Decorin genotypes, serum glucose, heart rate, and cerebrovascular events: the Tampere adult population cardiovascular risk study

    Genet. Test. Mol. Biomarkers

    (2016)
  • A. Ladwig et al.

    Osteopontin augments M2 microglia response and separates M1- and M2-polarized microglial activation in permanent focal cerebral ischemia

    Mediators Inflamm.

    (2017)
  • Cited by (28)

    • Microclots in subarachnoid hemorrhage: an underestimated factor in delayed cerebral ischemia?

      2022, Clinical Neurology and Neurosurgery
      Citation Excerpt :

      The hypercoagulable state is furthered by inactivity of plasmin, a natural fibrinolytic agent. Higher levels of plasminogen activator inhibitor-1 and peroxynitrite, an inactivator of plasminogen activator, have been reported after SAH [27,28]. Another study confirmed the importance of clotting factors vWF and ADAMTS-13.

    • Structural proteins: Major proteins of the extracellular matrix

      2021, Encyclopedia of Biological Chemistry: Third Edition
    View all citing articles on Scopus
    View full text